ClinicalTrials.gg
RecruitingNCT07559903Updated Oct 5, 2026

ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)

An observational study in Coronary Artery Disease, sponsored by Emory University. Recruiting at 19 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Emory University · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 5, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Coronary Artery Disease by Emory University — 1 open to participants now, 2 under way, none of them phase 3. Coronary Artery Disease · Emory University.

Planned enrollment
Largest of 10
5,000 · median 63
Started
2026
the only one that year
Observational
10 of 25
1 open now
Registered
25th of 25
by date

Among the 25 studies in Coronary Artery Disease by Emory University, this one has the largest planned enrollment of the 10 observational ones that give a count, is the only one that started in 2026, is one of 10 observational ones, and was the 25th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 25 studies in Coronary Artery Disease by Emory University is open now, in 3 countries.

By country, each count listing its studies:

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Coronary Artery Disease by Emory University, or all of them as a file.
02

Study summary

The primary objective of this protocol is to develop a comprehensive, multicenter international prospective registry to capture long-term clinical outcomes for adult patients undergoing percutaneous coronary intervention (PCI) with drug-coated balloons (DCB) for de novo coronary artery disease.

Read the detailed description

This database is designed as a prospective, international multi-center registry. The project aims to collect longitudinal data to evaluate the clinical performance of drug-coated balloons (DCB) in adult patients undergoing percutaneous coronary intervention (PCI) for de novo coronary artery disease. Emory will serve as the data coordinating center. All the participating sites will input information into Emory-hosted Redcap database. Data use agreements will be executed between Emory and each participating institution prior to data entry.

As a prospective registry, all clinical interventions, including the choice of DCB, vessel preparation techniques, and adjunct pharmacotherapy, are performed at the discretion of the treating physician according to the standard of care; no experimental interventions are mandated by this protocol.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Drug coated balloon
  • Percutaneous coronary intervention
  • Target lesion failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The participants are patients undergoing standard-of-care DCB PCI for de novo CAD at participating sites.

Eligibility will be determined by trained research personnel via a review of the EMR to ensure patients meet the inclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All adult patients (≥ 18 years of age) undergoing PCI for de novo CAD using DCB

Exclusion criteria

Exclusion Criteria:

  • Patients under the age of 18; PCI procedures without the utilization of DCB; PCI procedures for non de novo lesions
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Adults undergoing PCI with drug-coated balloons (DCB) for de novo coronary artery disease

    All adult patients undergoing percutaneous coronary intervention (PCI) with drug-coated balloons (DCB) for de novo coronary artery disease.

06

What researchers measure

Primary outcomes

  1. Incidence of Target Lesion Failure (TLF)

    Incidence of Target Lesion Failure (TLF), defined as the composite of cardiac death, target vessel myocardial infarction (TV-MI), or clinically driven target lesion revascularization (CD-TLR) will be documented.

    Time frame: At hospital discharge, 30 days, 6 months, and 12 months post-discharge, then yearly up to 5 years post-discharge

  2. Mortality and Myocardial Infarction

    Rates of all-cause mortality, cardiovascular death, and myocardial infarction (target vessel and non-target vessel) will be recorded.

    Time frame: At hospital discharge, 30 days, 6 months, and 12 months post-discharge, then yearly up to 5 years post-discharge

  3. Number of any repeat Revascularization

    Frequency of any repeat revascularization, specifically focusing on clinically driven TLR and clinically driven target vessel revascularization (TVR) will be assessed.

    Time frame: At hospital discharge, 30 days, 6 months, and 12 months post-discharge, then yearly up to 5 years post-discharge

  4. Incidence of Target Vessel Failure (TVF) and definite/probable vessel thrombosis

    The incidence of Target Vessel Failure (TVF) and definite/probable vessel thrombosis according to Academic Research Consortium (ARC) definitions will be documented.

    Time frame: At hospital discharge, 30 days, 6 months, and 12 months post-discharge, then yearly up to 5 years post-discharge

  5. Number of bleeding events

    The safety profile of post-procedural pharmacotherapy will be evaluated through the collection of bleeding events as defined by the Bleeding Academic Research Consortium (BARC) criteria.

    Time frame: At hospital discharge, 30 days, 6 months, and 12 months post-discharge, then yearly up to 5 years post-discharge

07

Study locations

4 of 19 sites recruiting
  • Banner University Medical Center
    Phoenix, Arizona 85006, United States
    Not yet recruiting
  • Holy Cross Health Fort Lauderdale
    Fort Lauderdale, Florida 33308, United States
    Not yet recruiting
    • Josh Purow, MD · Contact
    • Felipe Albuquerque, MD · Sub investigator
  • Emory University Hospital Midtown
    Atlanta, Georgia 30308, United States
    Recruiting
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
    Recruiting
  • Emory Saint Joseph's Hospital
    Atlanta, Georgia 30342, United States
    Recruiting
  • Emory Johns Creek Hospital
    Johns Creek, Georgia 30097, United States
    Recruiting
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
    Not yet recruiting
    • Imran Aslam · Contact
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Not yet recruiting
    • Kevin Croce · Contact
  • Allina Health Minneapolis Heart Institute
    Minneapolis, Minnesota 55407, United States
    Not yet recruiting
    • Manos Brilakis · Contact
  • The Mount Sinai Hospital
    New York, New York 10029, United States
    Not yet recruiting
    • Shamin Sharma · Contact
  • New York-Presbyterian/Weill Cornell Medical Center
    New York, New York 10065, United States
    Not yet recruiting
    • Jai Khatri · Contact
  • Montefiore Medical Center
    New York, New York 10467, United States
    Not yet recruiting
    • Azeem Latib · Contact
    • Louis Verreault-Julien · Sub investigator
    • Pier Pasquale Leone · Sub investigator
  • St. Francis Hospital & Heart Center
    Roslyn, New York 11576, United States
    Not yet recruiting
    • Ziad Ali · Contact
  • Sanger Heart & Vascular Institute
    Charlotte, North Carolina 28203, United States
    Not yet recruiting
    • Nyal Borges · Contact
  • Duke University Hospital
    Durham, North Carolina 27707, United States
    Not yet recruiting
    • Mariem Sawan · Contact
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Not yet recruiting
    • Bernardo Cortese · Contact
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Not yet recruiting
    • Leah Raj · Contact
  • Universitatsklinikum des Saarlandes
    Homberg (Efze), Germany
    Not yet recruiting
    • Bruno Scheller · Contact
  • University Clinical Centre of Serbia
    Belgrade, Serbia
    Not yet recruiting
    • Goran Stankovic · Contact
08

References and documents

Individual participant data

Plan to share: Yes — Individual de-identified participant data will be shared between sites. All clinical data will be shared including demographics, clinical characteristics, procedural characteristics, and outcomes

Supporting information: Study protocol, Statistical analysis plan

Time frame: The data will be available to our site continuously and upon request for other sites.

Access criteria: The data will be available upon request for other sites and will be shared with participating sites sub-investigators for analyses.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for May 2031, 58 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 58 months is above that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2026, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
Apr 30, 2026
StartActual
Jul 1, 2026was Jun 2026
Primary completionEst.
May 2031
CompletionEst.
May 2031
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→Jul 1, 2026 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Start date Jun 2026→Jul 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07559903
Lead sponsor
Emory University
Responsible party
Pratik Sandesara (Assistant Professor, Emory University) — Principal investigator
First posted
Apr 30, 2026
Start date
Jul 1, 2026
Primary completion
May 2031 (estimated)
Completion
May 2031 (estimated)
Last update
Oct 5, 2026

Study contacts

Daniel Gold, MD
Contact
daniel.alexander.gold@emory.edu
314-761-3396
Pratik Sandesara, MD
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion